Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection.

Sandler NG, Koh C, Roque A, Eccleston JL, Siegel RB, Demino M, Kleiner DE, Deeks SG, Liang TJ, Heller T, Douek DC.

Gastroenterology. 2011 Oct;141(4):1220-30, 1230.e1-3. doi: 10.1053/j.gastro.2011.06.063.

2.

Haemodynamic derangement in human immunodeficiency virus-infected patients with hepatitis C virus-related cirrhosis: the role of bacterial translocation.

Montes-de-Oca M, Blanco MJ, Marquez M, Soto MJ, Fernandez-Gutiérrez C, Rodriguez-Ramos C, Giron-Gonzalez JA.

Liver Int. 2011 Jul;31(6):850-8. doi: 10.1111/j.1478-3231.2011.02505.x. Retraction in: Liver Int. 2012 Sep;32(8):1325.

PMID:
21645216
3.

Microbial translocation and liver disease progression in women coinfected with HIV and hepatitis C virus.

French AL, Evans CT, Agniel DM, Cohen MH, Peters M, Landay AL, Desai SN.

J Infect Dis. 2013 Aug 15;208(4):679-89. doi: 10.1093/infdis/jit225.

4.

Low levels of microbial translocation marker LBP are associated with sustained viral response after anti-HCV treatment in HIV-1/HCV co-infected patients.

Nyström J, Stenkvist J, Häggblom A, Weiland O, Nowak P.

PLoS One. 2015 Mar 18;10(3):e0118643. doi: 10.1371/journal.pone.0118643.

5.

Markers of microbial translocation predict hypertension in HIV-infected individuals.

Manner IW, Baekken M, Kvale D, Oektedalen O, Pedersen M, Nielsen SD, Nowak P, Os I, Trøseid M.

HIV Med. 2013 Jul;14(6):354-61. doi: 10.1111/hiv.12015.

6.

Globulin-platelet model predicts minimal fibrosis and cirrhosis in chronic hepatitis B virus infected patients.

Liu XD, Wu JL, Liang J, Zhang T, Sheng QS.

World J Gastroenterol. 2012 Jun 14;18(22):2784-92. doi: 10.3748/wjg.v18.i22.2784.

7.

Liver fibrosis, microbial translocation and immune activation markers in HIV and HCV infections and in HIV/HCV co-infection.

Sacchi P, Cima S, Corbella M, Comolli G, Chiesa A, Baldanti F, Klersy C, Novati S, Mulatto P, Mariconti M, Bazzocchi C, Puoti M, Pagani L, Filice G, Bruno R.

Dig Liver Dis. 2015 Mar;47(3):218-25. doi: 10.1016/j.dld.2014.11.012.

PMID:
25544657
8.

Expression of interleukin-17 associated with disease progression and liver fibrosis with hepatitis B virus infection: IL-17 in HBV infection.

Du WJ, Zhen JH, Zeng ZQ, Zheng ZM, Xu Y, Qin LY, Chen SJ.

Diagn Pathol. 2013 Feb 28;8:40. doi: 10.1186/1746-1596-8-40.

9.

Effects of Co-Trimoxazole on Microbial Translocation in HIV-1-Infected Patients Initiating Antiretroviral Therapy.

Vesterbacka J, Barqasho B, Häggblom A, Nowak P.

AIDS Res Hum Retroviruses. 2015 Aug;31(8):830-6. doi: 10.1089/AID.2014.0366.

PMID:
26059763
10.

Plasma levels of soluble CD14 independently predict mortality in HIV infection.

Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, Pedersen C, Ruxrungtham K, Lewin SR, Emery S, Neaton JD, Brenchley JM, Deeks SG, Sereti I, Douek DC; INSIGHT SMART Study Group..

J Infect Dis. 2011 Mar 15;203(6):780-90. doi: 10.1093/infdis/jiq118.

11.

Evaluation of bacterial translocation in patients with chronic HCV infection.

Munteanu D, Negru A, Radulescu M, Mihailescu R, Arama SS, Arama V.

Rom J Intern Med. 2014 Apr-Jun;52(2):91-6.

PMID:
25338345
12.

Human immunodeficiency virus-related microbial translocation and progression of hepatitis C.

Balagopal A, Philp FH, Astemborski J, Block TM, Mehta A, Long R, Kirk GD, Mehta SH, Cox AL, Thomas DL, Ray SC.

Gastroenterology. 2008 Jul;135(1):226-33. doi: 10.1053/j.gastro.2008.03.022.

14.

Different biological significance of sCD14 and LPS in HIV-infection: importance of the immunovirology stage and association with HIV-disease progression markers.

Romero-Sánchez M, González-Serna A, Pacheco YM, Ferrando-Martínez S, Machmach K, García-García M, Alvarez-Ríos AI, Vidal F, Leal M, Ruiz-Mateos E.

J Infect. 2012 Nov;65(5):431-8. doi: 10.1016/j.jinf.2012.06.008.

PMID:
22728172
15.

Soluble CD14 in cerebrospinal fluid is associated with markers of inflammation and axonal damage in untreated HIV-infected patients: a retrospective cross-sectional study.

Jespersen S, Pedersen KK, Anesten B, Zetterberg H, Fuchs D, Gisslén M, Hagberg L, Trøseid M, Nielsen SD.

BMC Infect Dis. 2016 Apr 21;16:176. doi: 10.1186/s12879-016-1510-6.

16.

Lipopolysaccharide, immune activation, and liver abnormalities in HIV/hepatitis B virus (HBV)-coinfected individuals receiving HBV-active combination antiretroviral therapy.

Crane M, Avihingsanon A, Rajasuriar R, Velayudham P, Iser D, Solomon A, Sebolao B, Tran A, Spelman T, Matthews G, Cameron P, Tangkijvanich P, Dore GJ, Ruxrungtham K, Lewin SR.

J Infect Dis. 2014 Sep 1;210(5):745-51. doi: 10.1093/infdis/jiu119.

17.

Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study.

Marchetti G, Cozzi-Lepri A, Tincati C, Calcagno A, Ceccherini-Silberstein F, De Luca A, Antinori A, Castagna A, Puoti M, Monforte Ad; Icona Foundation Study Group..

BMC Infect Dis. 2014 Feb 12;14:79. doi: 10.1186/1471-2334-14-79.

18.

Predictive value of liver enzymes and inflammatory biomarkers for the severity of liver fibrosis stage in HIV/HCV co-infected patients.

Charpentier C, Champenois K, Gervais A, Landman R, Joly V, Le Gac S, Larrouy L, Damond F, Brun-Vézinet F, Descamps D, Yazdanpanah Y.

PLoS One. 2013;8(3):e59205. doi: 10.1371/journal.pone.0059205.

19.

Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy.

Loras C, Gisbert JP, Mínguez M, Merino O, Bujanda L, Saro C, Domenech E, Barrio J, Andreu M, Ordás I, Vida L, Bastida G, González-Huix F, Piqueras M, Ginard D, Calvet X, Gutiérrez A, Abad A, Torres M, Panés J, Chaparro M, Pascual I, Rodriguez-Carballeira M, Fernández-Bañares F, Viver JM, Esteve M; REPENTINA study.; GETECCU (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa) Group..

Gut. 2010 Oct;59(10):1340-6. doi: 10.1136/gut.2010.208413.

PMID:
20577000
20.

Variations in serum sphingolipid levels associate with liver fibrosis progression and poor treatment outcome in hepatitis C virus but not hepatitis B virus infection.

Grammatikos G, Ferreiros N, Bon D, Schwalm S, Dietz J, Berkowski C, Fitting D, Herrmann E, Zeuzem S, Sarrazin C, Pfeilschifter J.

Hepatology. 2015 Mar;61(3):812-22. doi: 10.1002/hep.27587.

PMID:
25348752
Items per page

Supplemental Content

Support Center